NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $1.69 +0.01 (+0.60%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Skye Bioscience Stock (NASDAQ:SKYE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$1.68▼$1.7750-Day Range$1.57▼$4.6752-Week Range$1.50▼$14.08Volume13,582 shsAverage Volume61,070 shsMarket Capitalization$7.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Skye Bioscience, Inc. (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company focused on developing medicines that modulate the endocannabinoid system, with an emphasis on the cannabinoid CB1 receptor. The company’s research is aimed at addressing metabolic, inflammatory and fibrotic diseases while seeking to avoid the central nervous system effects associated with conventional CB1-targeting compounds. Skye’s lead program is nimacimab, a peripherally restricted monoclonal antibody designed to inhibit CB1 receptor activity outside the brain. The therapy has been evaluated in clinical studies involving obesity and related metabolic conditions, including nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis. Skye has also historically developed SBI-100 Ophthalmic Emulsion, an investigational CB1 receptor agonist studied for glaucoma and ocular hypertension. Founded in 2011 and headquartered in San Diego, California, Skye has concentrated its operations on research, clinical development and collaborations supporting its cannabinoid-based drug candidates. Punit Dhillon is a co-founder and has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Skye Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingSkye Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSkye Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Skye Bioscience are expected to grow in the coming year, from ($5.04) to ($4.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkye Bioscience has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.82% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 1.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 9.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $889,198.00 in company stock.Percentage Held by Insiders6.20% of the stock of Skye Bioscience is held by insiders.Percentage Held by Institutions21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SKYE Stock News HeadlinesIl direttore di Skye Bioscience Andrew Schwab vende azioni per $239.555September 25, 2026 | it.investing.comSkye Bioscience (NASDAQ:SKYE) Stock: Insider Andrew Schwab Sells 28,700 SharesSeptember 25, 2026 | insidertrades.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) StockSeptember 19, 2026 | insidertrades.comSkye Bioscience average analyst price target raised 10.29% to $61.20September 15, 2026 | msn.comSkye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the moveAugust 26, 2026 | msn.comSkye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks TranscriptAugust 14, 2026 | seekingalpha.comSkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsAugust 14, 2026 | globenewswire.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $5.9976 at the beginning of the year. Since then, SKYE shares have decreased by 71.2% and is now trading at $1.7250. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. When did Skye Bioscience's stock split? Skye Bioscience's stock reverse split on the morning of Monday, August 24th 2026.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 23rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Skye Bioscience IPO? Skye Bioscience (SKYE) raised $100,000 in an IPO on Thursday, April 11th 2024. The company issued 2,000,000 shares at a price of $0.05 per share. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings8/14/2026Today10/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SKYE's financial health is in the Red zone, according to TradeSmith. SKYE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SKYE Previous SymbolOTCMKTS:EMBI CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees12Year Founded2012Profitability EPS (Trailing Twelve Months)($10.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-329.08% Return on Assets-201.79% Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book0.34Miscellaneous Outstanding Shares4,428,000Free Float4,153,000Market Cap$7.48 million OptionableOptionable Beta2.86 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SKYE) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
